Zheyuan Technology is a platform-based company incubated by the Institute of Computing Technology, Chinese Academy of Sciences, which empowers medical innovation with digital life technology. The company has the world's leading digital twin technology of life functions, which enables the systematic presentation of new tumor targets, accurate assessment of dominant indications, and accurate prediction of patient response. The company already has a number of high-value IPs such as new targets, new indications, and drug companion diagnostics. Zheyuan is committed to building a "drug digital test field", breaking through the bottleneck of biochemical technology, improving the efficiency of drug research and development, the success rate of clinical trials, and the efficiency of clinical treatment, introducing a new paradigm for medical research and development, and escorting human health.
The Institute of Computing Technology of the Chinese Academy of Sciences and Zheyuan Technology jointly established the Turing-Darwin Laboratory, the first to advocate "computational medicine", with systems theory as the guiding ideology, intensive data-driven research paradigm, artificial intelligence as the method, high-performance computing In order to support, undertake the technical research work of the intersection of biomedicine and computational science.
Total Funding: $12.9M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 51 to 100
Founded: 2015